Volume 11 Issue 151
Published - 14:00 UTC 08:00 EST 12-Jun-2009 
Next Update - 14:00 UC 08:00 EST 13-Jun-2009

Editor: Susan K. Boyer, RN
© Vidyya.
All rights reserved.




  

 




HPV status can predict outcome in oropharyngeal cancer 

(12 June 2009: VIDYYA MEDICAL NEWS SERVICE) -- Patients with advanced forms of a cancer in the upper portion of their throat have better outcomes if their tumors are positive for the human papillomavirus (HPV), according to new data from a phase III clinical trial presented at the ASCO annual meeting. Although other studies have suggested a link between HPV status and outcome in patients who have oropharyngeal cancer, these new data provide the most definitive evidence, said the study’s leader, Dr. Maura Gillison of Ohio State University, at a recent press briefing.

Oropharyngeal cancer “can now be divided into those linked to prolonged use of tobacco and alcohol, and those linked to HPV,” she said. And determining HPV status, she added, “may now be part of routine clinical care…because of its prognostic implications in these patients.”

The findings come from a correlative study in the Radiation Therapy Oncology Group (RTOG) 0129 clinical trial, a phase III trial in which patients with stage III or IV oropharyngeal cancer were randomly assigned to receive different regimens of radiotherapy and the chemotherapy drug cisplatin. Nearly two-thirds of the tumor samples tested HPV-positive, Dr. Gillison said. Two years after treatment, 88 percent of the HPV-positive patients were still alive, compared with 66 percent of the HPV-negative patients. The absolute difference in survival increased over time.

Additional analyses ruled out other factors, such as age, performance status, and treatment, which might account for the superior outcomes seen in patients with HPV-positive tumors.

Due to the dramatic differences in treatment response, Dr. Gillison said, from this point forward RTOG and the Eastern Clinical Oncology Group will stratify all of their clinical trials by HPV status, and they will design clinical trials specifically for HPV-positive or -negative patients.

Return to Vidyya Medical News Service for 12 June 2009

© Vidyya. All rights reserved.

Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.

Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.